Bank of America’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-14,500
Closed -$3M 8200
2024
Q2
$3M Hold
14,500
﹤0.01% 4095
2024
Q1
$3.93M Buy
+14,500
New +$3.46M ﹤0.01% 3846
2014
Q1
Sell
-60,000
Closed -$3.18M 7827
2013
Q4
$3.18M Buy
+60,000
New +$3.01M ﹤0.01% 2880
2013
Q3
Sell
-15,000
Closed -$615K 7886
2013
Q2
$615K Buy
+15,000
New +$643K ﹤0.01% 4550

Other funds holding CRL

Bank of America's CRL Position: Q1 2026 in Review

Bank of America increased its Charles River Laboratories (CRL) stake by 5% in Q1 2026, buying an estimated $10.1M and bringing the position to 1,135,027 shares worth $196M. The position accounts for 0.01% of the portfolio, ranked #748.

Bank of America first reported a position in CRL in Q2 2013 and has held it in 52 quarters since. The position peaked at $241M in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Bank of America held 1,135,027 shares of Charles River Laboratories worth $196M as of Q1 2026.
  • Bank of America bought 54,500 Charles River Laboratories shares in Q1 2026, an estimated $10.1M.
  • Charles River Laboratories made up 0.01% of Bank of America's portfolio in Q1 2026, its #748 holding.
  • Bank of America first reported a position in Charles River Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Charles River Laboratories position peaked at $241M in Q1 2024.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.